VE-303,PMN310
ProMIS Neurosciences,PureTech Health
[]
 announces fda clearance of ind application for pmn310 in alzheimer s disease. receives fast track designation for ve303 and presents phase 2 data at digestive disease week. get a more detailed analysis: (3/3)
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry